secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202414
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences names Natalie Holles CEO; CoMpass trial enrollment at 86 patients, nearing completion
--------------------------------------------------------------------------------

- New CEO Natalie Holles, former CEO of Third Harmonic Bio and Audentes, appointed effective April 30, 2026.
- Founder Elisabet de los Pinos steps down as CEO and director; remains as consultant through October 2026.
- Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has 86 patients enrolled; >25 additional patients identified for screening.
- Company reiterates guidance: enrollment completion by mid-2026, topline data in H2 2027.
- ATM prospectus terminated; $6.7M gross proceeds raised from 1.06M shares sold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/0001193125-26-202414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526202414/d117008d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer